Skip to main content
GENB
NASDAQ Life Sciences

Generate Biomedicines Launches Armored CAR T Trial for Ovarian Cancer

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$15.06
Mkt Cap
$1.928B
52W Low
$11
52W High
$22.67
52W Position info
37% above low
Off High info
34% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

GENB sits 37% above its 52-week low of $11.

Summary

Generate Biomedicines and Roswell Park have launched an exclusive clinical trial of GB-5267, an 'armored' CAR T therapy for ovarian cancer, and have dosed the first patient in the Phase 1 trial. The therapy is designed to avoid pre-infusion chemotherapy and targets the MUC16 biomarker, which is present in over 80% of ovarian tumors. This is a new clinical milestone for the company, expanding its pipeline into solid tumors. The trial launch follows positive Phase 1 data for GB-0895 in asthma and COPD disclosed in August. The company's cash position of $457.4 million supports advancement of this program.

At the time of this announcement, GENB was trading at $15.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $11.00 to $22.67. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

GENB - Latest Insights

GENB
Oct 13, 2026, 4:27 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $12.40
Real-time Price: $14.16 info
Change: +$1.76 (+14%) info
Market Cap: $1.817B info
GENB
Aug 25, 2026, 7:28 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $20.54
Real-time Price: $14.16 info
Change: -$6.38 (-31%) info
Market Cap: $1.817B info
GENB
Aug 06, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $14.30
Real-time Price: $14.16 info
Change: -$0.1401 (-0.98%) info
Market Cap: $1.817B info
GENB
Aug 06, 2026, 6:01 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $14.31
Real-time Price: $14.16 info
Change: -$0.1501 (-1%) info
Market Cap: $1.817B info
GENB
Aug 06, 2026, 6:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.31
Real-time Price: $14.16 info
Change: -$0.1501 (-1%) info
Market Cap: $1.817B info